Volume 4 (Issue 1, 2, 3) 2019
Review
Autism Spectrum Disorder: Medications overview
https://doi.org/10.37881/1.411
2019, Volume 4, Issue 1, January-April [Download full PDF]
Review
FDA-approves the first therapy in 2018 for the seizures associated with Dravet syndrome
https://doi.org/10.37881/1.412
2019, Volume 4, Issue 1, January-April [Download full PDF]
Review
Cannabidiol: FDA approved new drug for the Lennox-Gastaut syndrome and Dravet syndrome: Pharmacotherapeutics review
https://doi.org/10.37881/1.413
2019, Volume 4, Issue 1, January-April [Download full PDF]
Review
Caplacizumab: First FDAapproved therapy in 2019 for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura
https://doi.org/10.37881/1.414
2019, Volume 4, Issue 1, January-April [Download full PDF]
Review
Stiripentol: New approved drug for the Dravet syndrome: Pharmacotherapeutics review
https://doi.org/10.37881/1.415
2019, Volume 4, Issue 1, January-April [Download full PDF]
Review
Siponimod: A new approved oral drug to treat multiple sclerosis
https://doi.org/10.37881/1.421
2019, Volume 4, Issue 2, May-August [Download full PDF]
Review
Istradefylline: A new add-on drug to treat off episodes in adults with Parkinson’s disease
https://doi.org/10.37881/1.422
2019, Volume 4, Issue 2, May-August [Download full PDF]
Review
FDA recalled Ranitidine: What about the consumers who ate Ranitidine with carcinogenic impurity by paying to Pharma companies?
https://doi.org/10.37881/1.431
2019, Volume 4, Issue 3, Sept-Dec [Download full PDF]
Review
Top Pharma companies not following current good manufacturing processes: Angiotensin II receptor blockers with carcinogenic impurities: A threat to global public health
https://doi.org/10.37881/1.432
2019, Volume 4, Issue 3, Sept-Dec [Download full PDF]